Gain Therapeutics

Hearing loss is a big risk factor for developing Parkinson's: Study https://lnkd.in/e9YiXu2Z

Gain Therapeutics Presents Data at the 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 Read the full press release here: https://lnkd.in/gPr9QRS4

Gain Therapeutics Presents Preclinical GT-02287 Data at #SfN24. “The preservation of motor and cognitive improvement in animal models of Parkinson’s disease associated with GT-02287 after its discontinuation coupled with the neuroprotective effects after delayed administration support the potential of GT-02287 to slow or stop the progression of Parkinson’s disease,” said Gene Mack, Interim CEO and CFO of Gain Therapeutics. “The potential of GCase as a therapeutic target beyond Parkinson’s Disease is an encouraging finding that we can incorporate into our future development plans for GT-02287.” Read the full press release here: https://lnkd.in/gj6QMFZ8

We look forward to presenting a poster detailing the use of the Company’s Magellan platform to discover novel allosteric discoidin domain receptor 2 (DDR2) inhibitors, which will be presented this week at the 36th EORTC-NCI-AACR (ENA) Symposium on molecular targets and #cancer therapeutics being held October 23-25 in Barcelona, Spain. DDR2 displays aberrant expression and mutations across various cancer types and is involved in critical processes in tumor progression, including proliferation, migration, invasion, metastasis, epithelial-mesenchymal transition, and #chemotherapy resistance. Allosteric small molecule inhibitors have the potential to overcome resistance and offer enhanced selectivity and safety compared to traditional kinase inhibitors. Title: Identification of allosteric inhibitors targeting Discoidin Domain Receptor 2 (DDR2)  Presenting Author: Sara Cano-Crespo, Ph.D., Gain Therapeutics Poster Session: Molecular Targeted Agents Date and Time: Wednesday, October 23, 2024, 11am CEST https://lnkd.in/drZSZZrm

We look forward to presenting a poster detailing the use of the Company’s Magellan platform to discover novel allosteric discoidin domain receptor 2 (DDR2) inhibitors, which will be presented this week at the 36th EORTC-NCI-AACR (ENA) Symposium on molecular targets and #cancer therapeutics being held October 23-25 in Barcelona, Spain. DDR2 displays aberrant expression and mutations across various cancer types and is involved in critical processes in tumor progression, including proliferation, migration, invasion, metastasis, epithelial-mesenchymal transition, and #chemotherapy resistance. Allosteric small molecule inhibitors have the potential to overcome resistance and offer enhanced selectivity and safety compared to traditional kinase inhibitors. Title: Identification of allosteric inhibitors targeting Discoidin Domain Receptor 2 (DDR2)  Presenting Author: Sara Cano-Crespo, Ph.D., Gain Therapeutics Poster Session: Molecular Targeted Agents Date and Time: Wednesday, October 23, 2024, 11am CEST https://lnkd.in/drZSZZrm

Many thanks to the The Michael J. Fox Foundation for Parkinson's Research for organizing a wonderful 16th Annual PD Therapeutics Conference. We are grateful not only for those at Gain and MJFF but for all the scientific minds around the world who strive for a future where a cure to Parkinson’s disease exists. We’re in this together - and may the future be sooner rather than later.

The Michael J. Fox Foundation for Parkinson's Research ...Thank you to the amazing people at MJFF for organizing such an important conference to share new clinical research in Parkinson's Disease. Gain Therapeutics (GANX) is so very grateful for the invitation to present new clinical data for GT-02287 and all the support we receive from MJFF. It is difficult not to feel optimistic for PD patients everywhere with so many groups working hard on the underlying disease pathology to deliver better outcomes in PD... New and better help for patients is on the way!

Looking forward to attending and presenting tomorrow at The Michael J. Fox Foundation for Parkinson's Research 16th Annual Parkinson’s Disease Therapeutics Conference. The oral presentation titled, “Brain-penetrant small molecule GT-02287 is well-tolerated in healthy volunteers, shows GCase target engagement, and achieves therapeutic exposures shown to modulate PD pathobiology in preclinical models,” will be presented as part of the conference’s first session, “Progress in the Therapeutics Pipeline”. “We look forward to presenting Phase 1 data for GT-02287, in development for the treatment of Parkinson’s disease, at the upcoming MJFF conference and appreciate the opportunity to contextualize these data with exciting preclinical data that have been generated recently for GT-02287. The Michael J. Fox Foundation shares our mission of bringing potentially life-changing treatments to people living with Parkinson’s disease,” commented Jonas Hannestad. https://lnkd.in/dcJN2znB

Thank you NeurologyLive. Understanding the Therapeutic Potential of GT-02287 in GBA-#Parkinsons Disease https://lnkd.in/eKS6AkBq

Gain Therapeutics Announces Poster Presentation at #ENASymp24 Read the full press release here: https://lnkd.in/eHp-kWeU